- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | A CRISPR cure for cystic fibrosis? | ||
| Do | BrainsWay shows initial success in treating adult ADHD with deep magnetic stimulation | ||
| Do | EuroBiotech Report-GSK's TCR deal, Vifor, PharmaMar filing, NeoTX series C and Novimmune | ||
| Do | Spruce nets $88M to push rare disease drug into late-stage trial | ||
| Do | Everest hires ex-Lilly leader to oversee push for Chinese market | ||
| Do | Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO | ||
| Do | Pfizer teams up with Saama for AI clinical data mining | ||
| Do | GSK pays $50M for 2 solid tumor cell therapies from Immatics | ||
| Do | CMR Surgical rolls out modular surgery robot to NHS hospitals | ||
| Mi | Five Prime grabs $5M lifeline in Seattle Genetics ADC deal | ||
| Mi | Acutus secures FDA clearance for new real-time heart mapping algorithm | ||
| Mi | Gilead poaches Bristol-Myers oncology executive to lead research biology | ||
| Mi | Insulet will connect Abbott, Dexcom CGMs with its digital, wearable insulin pump | ||
| Mi | Worldwide Clinical Trials boosts exec team with new early-phase lead | ||
| Mi | Incyte hits endpoint in 2nd pivotal atopic dermatitis trial | ||
| Mi | Ex-PixarBio CEO sentenced to 7 years for defrauding investors | ||
| Mi | Israeli biotech NeoTX lands $45M series C for combo I-O cancer trials | ||
| Di | Five Prime Therapeutics' pancreatic cancer combo with Opdivo a bust | ||
| Di | Baxter probe finds accounting errors leading to $276M in inflated income | ||
| Di | Grail kicks off its first study to provide doctors with real-world results from its multi-cancer blood test | ||
| Di | 'Closer to the science': Why Amgen vets Harper and Seidenberg set up their own VC shop | ||
| Di | Crossover round, check. New team of biopharma execs, check. Now, Imara wants an IPO | ||
| Di | PharmaMar, Jazz get FDA priority review for lung cancer drug | ||
| Di | Gene therapy tackles tau tangles in mouse models of dementia | ||
| Di | Vifor buys priority review voucher for undisclosed filing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
